Plasma levels of the soluble fraction of tumor necrosis factor receptors 1 and 2 are independent determinants of plasma cholesterol and LDL-cholesterol concentrations in healthy subjects

Atherosclerosis

Volumn 146, Issue 2, 1999, Pages 321-327

  Fernández Real, José Manuel ^a   Gutiérrez, Cristina ^b   Ricart, Wifredo ^a   Castiñeira, María José ^c   Vendrell, Joan ^b   Richart, Cristóbal ^b  

^a Hospital Universitari   (Spain)

^b HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Cholesterol; LDL cholesterol; TNF alpha; TNF alpha receptors; Triglycerides

Indexed keywords

CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RECEPTOR SUBTYPE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ADULT; ARTICLE; BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; MALE; NORMAL HUMAN; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; ANTIGENS, CD; BIOLOGICAL MARKERS; BODY MASS INDEX; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; FEMALE; HUMANS; IMMUNOASSAY; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; REFERENCE VALUES; TRIGLYCERIDES; ULTRACENTRIFUGATION;

EID: 0345465925     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00156-2     Document Type: Article

References (32)

1. Beutler B., Cerami A. The biology of cachectin/TNF-α primary mediator of the host response. Annu Rev Immunol. 7:1989;625-655.
2. Grunfeld C., Feingold K.R. The metabolic effects of tumor necrosis factor and other cytokines. Biotherapy. 3:1991;143-158.
3. Grunfeld C., Feingold K.R. Role of cytokines in inducing hyperlipidemia. Diabetes. 41(Suppl 2):1992;97-101.
4. Grunfeld C., Pang M., Doerrler W., Shigenaga J.K., Jensen P., Feingold K.R. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 74:1992;1045-1052.
5. Levy E., Gurbindo C., Lacaille F., Paradis K., Thibault L., Seidman E. Circulating tumor necrosis factor-α levels and lipid abnormalities in patients with cystic fibrosis. Pediatr Res. 34:1993;162-166.
6. Memon R.A., Grunfeld C., Moser A.H., Feingold K.R. Tumor necrosis factor mediates the effect of endotoxin on cholesterol and triglyceride metabolism in mice. Endocrinology. 132:1993;2246-2253.
7. Tartaglia L.A., Goeddel D.V. Two TNF receptors. Immunol Today. 13:1992;151-153.
8. Smith C.A., Farrah T., Goodwin R.G. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation and death. Cell. 76:1994;959-962.
9. Bazzoni F., Beutler B. The tumor necrosis factor ligand and receptor families. New Engl J Med. 334:1996;1717-1725.
10. Olsson I., Lantz M., Nilsson E., Peetre C., Thysell H., Grubb A. Isolation and characterization of a tumor necrosis factor binding protein from urine. Eur J Haematol. 42:1989;270-275.
11. Nophar Y., Kemper O., Brakebusch C., Engelmann H., Zwang R., Aderka D. et al. Soluble forms of tumor necrosis factors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor. EMBO J. 9:1990;3269-3278.
12. Aderka D., Engelmann H., Maor Y., Brakebusch C., Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med. 175:1992;323-329.
13. Smith R.A., Baglioni C. The active form of tumor necrosis factor is a trimer. J Biol Chem. 262:1987;6951-6954.
14. Fernández-Real J.M., Broch M., Ricart W., Gutiérrez C., Casamitjana R., Vendrell J. et al. Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance. Diabetes. 47:1998;1757-1762.
15. Siedel J., Hagele E.O., Ziegenhorn J., Wahlefeld A.W. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem. 29:1983;1075-1080.
16. Kostner G.M., Molinari E., Pichler P. Evaluation of a new HDL2/HDL3 quantitation method based on precipitation with polyethylene glycol. Clin Chim Acta. 148:1985;139-147.
17. Wahlefeld A.W. Lipoproteins. Bergmeyer H.U. Methoden der enzymatischen analyse. II:1974;187-188 Verlag Chemie, Weinheim.
18. Hotamisligil G.S., Arner P., Atkinson R.L., Spiegelman B.M. Differential regulation of the p80 tumor necrosis factor receptor in human obesity and insulin resistance. Diabetes. 46:1997;451-455.
19. Aderka D., Engelmann H., Hornik V., Skornick Y., Levo Y., Wallach D. et al. Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res. 51:1991;5602-5607.
20. Peschon J.J., Slack J.L., Reddy P., Stocking K.L., Sunnarborg S.W., Lee D.C. et al. An essential role for ectodomain shedding in mammalian development. Science. 282:1998;1281-1284.
21. Preece G., Murphy G., Ager A. Metalloproteinase-mediated regulation of L-selectin levels on leucocytes. J Biol Chem. 271:1996;11634-11640.
22. Sampietro T., Tuoni M., Ferdeghini M., Ciardi A., Marraccini P., Prontera C. et al. Plasma cholesterol regulates soluble cell adhesion molecule expression in familial hypercholesterolemia. Ciculation. 96:1997;1381-1385.
23. Vogel R.A., Corretti M.C., Gellman J. Cholesterol, cholesterol lowering, and endothelial function. Prog Cardiovasc Dis. 41:1998;117-136.
24. Ettinger W.H., Miller L.D., Albers J.J., Smith T.K., Parks J.S. Lipopolysaccharide and tumor necrosis factor cause a fall in plasma concentration of lecithin:cholesterol acyltransferase in cynomolgus monkeys. J Lipid Res. 31:1990;1099-1107.
25. Lopes-Virella M., Virella G. Cytokines, modified lipoproteins, and arteriosclerosis in diabetes. Diabetes. 45(Suppl 3):1996;40-44.
26. Brito B.E., Romano E.L., Grunfeld C. Increased lipopolysaccharide-induced tumour necrosis factor levels and death in hypercholesterolaemic rabbits. Clin Exp Immunol. 101:1995;357-361.
27. Henninger D.D., Gerritsen M.E., Granger D.N. Low-density lipoprotein receptor knockout mice exhibit exaggerated microvascular responses to inflammatory stimuli. Circ Res. 81:1997;274-281.
28. Fleet J.C., Clinton S.K., Salomon R.N., Loppnow H., Libby P. Atherogenic diets enhance endotoxin-stimulated interleukin-1 and tumor necrosis factor gene expression in rabbit aortae. J Nutr. 122:1992;294-305.
29. Lawler J.F. Jr, Yin M., Diehl A.M., Roberts E., Chatterjee S. Tumor necrosis factor-alpha stimulates the maturation of sterol regulatory element binding protein-1 in human hepatocytes through the action of neutral sphingomyelinase. J Biol Chem. 273:1998;5053-5059.
30. Chait A., Bierman E.L., Albers J.J. Low density lipoprotein receptor activity in cultured human skin fibroblasts: mechanism of insulin-induced stimulation. J Clin Invest. 64:1979;1309-1319.
31. Stames H.H. Jr, Warren R.S., Jeevsnadern M., Gabrilovic J.L., Lerchien W., Oettgen H.F. et al. Tumor necrosis factor and the acute metabolic response to injury in man. J Clin Invest. 82:1988;1321-1325.
32. Jovinge S., Hamsten A., Tornvall P., Proudler A., Bavenholm P., Ericsson C.G. et al. Evidence for a role of tumor necrosis factor alpha in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease. Metabolism. 47:1998;113-118.